Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2009Hemoglobin

Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMaria Domenica CappelliniFondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoKMKhaled M. MusallamKhalifa University of Science and TechnologyATAlì TaherAmerican University of Beirut Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cappellini et al. (2009) studied this question.

synapsesocial.com/papers/6a795be1684c0941cf320de9https://doi.org/10.3109/03630260903346924
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combined therapy with deferiprone and desferrioxamine1998 · 218 citations
  2. 2Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis2005 · 496 citations
  3. 3New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review1995 · 87 citations
  4. 4Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major2005 · 374 citations
  5. 5Four‐year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β‐thalassaemia major: comparison between different chelation regimens2006 · 34 citations